XERS
Closed
Xeris Pharmaceuticals Inc
2.51
-0.02 (-0.79%)
Last Update: 06 Sep 2024 23:28:00
Yesterday: 2.53
Day's Range: 2.49 - 2.63
Send
sign up or login to leave a comment!
When Written:
2.07
Xeris Pharmaceuticals Inc is a biopharmaceutical company that develops and commercializes innovative treatments for patients with serious and life-threatening conditions. The company is focused on developing and commercializing ready-to-use, liquid-stable injectables and formulations for use in a variety of therapeutic areas, including diabetes, epilepsy, and hypoglycemia.
Xeris Pharmaceuticals was founded in 2005 and is headquartered in Chicago, Illinois. The company's lead product, Gvoke HypoPen, is a pre-filled, single-use glucagon pen used to treat severe hypoglycemia in patients with diabetes.
In addition to Gvoke HypoPen, Xeris Pharmaceuticals has a pipeline of other products in development, including XeriSol™ and XeriJect™, which are designed to improve the delivery of existing drugs, as well as novel formulations for the treatment of epilepsy and other neurological disorders.
The company has partnerships with several pharmaceutical companies, including Novo Nordisk and Zealand Pharma, to develop and commercialize new products. Xeris Pharmaceuticals is committed to improving the lives of patients through innovative solutions that address unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Xeris Pharmaceuticals was founded in 2005 and is headquartered in Chicago, Illinois. The company's lead product, Gvoke HypoPen, is a pre-filled, single-use glucagon pen used to treat severe hypoglycemia in patients with diabetes.
In addition to Gvoke HypoPen, Xeris Pharmaceuticals has a pipeline of other products in development, including XeriSol™ and XeriJect™, which are designed to improve the delivery of existing drugs, as well as novel formulations for the treatment of epilepsy and other neurological disorders.
The company has partnerships with several pharmaceutical companies, including Novo Nordisk and Zealand Pharma, to develop and commercialize new products. Xeris Pharmaceuticals is committed to improving the lives of patients through innovative solutions that address unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
2.07
Xeris Pharmaceuticals Inc is a biopharmaceutical company that develops and commercializes innovative treatments for patients with diabetes and other serious medical conditions. The company's proprietary formulation technology enables the development of stable, ready-to-use liquid formulations of injectable drugs, which can be administered subcutaneously or intramuscularly without the need for reconstitution or refrigeration.
Xeris Pharmaceuticals' lead product, Gvoke HypoPen, is the first pre-filled, ready-to-use glucagon autoinjector for severe hypoglycemia in adults and children with diabetes. The company also has a pipeline of other products in development, including a ready-to-use glucagon rescue pen for exercise-induced hypoglycemia, a ready-to-use diazepam autoinjector for seizure clusters, and a ready-to-use pramlintide insulin combination for type 1 diabetes.
Xeris Pharmaceuticals was founded in 2005 and is headquartered in Chicago, Illinois. The company went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol XERS.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Xeris Pharmaceuticals' lead product, Gvoke HypoPen, is the first pre-filled, ready-to-use glucagon autoinjector for severe hypoglycemia in adults and children with diabetes. The company also has a pipeline of other products in development, including a ready-to-use glucagon rescue pen for exercise-induced hypoglycemia, a ready-to-use diazepam autoinjector for seizure clusters, and a ready-to-use pramlintide insulin combination for type 1 diabetes.
Xeris Pharmaceuticals was founded in 2005 and is headquartered in Chicago, Illinois. The company went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol XERS.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!